Description {#s1}
===========

A 12-year-old boy presents with a 2-week history of a generalised maculopapular exanthem on the trunk, arms and legs 4 weeks after a full recovery from COVID-19. During the COVID-19 acute infection (nasopharyngeal swab tested for SARS-CoV-2 RNA amplification result positive), he developed fevers greater than 39°C for 48 hours, sore throat, abdominal pain and diarrhoea lasting a week. Four weeks after full recovery of all symptoms, a generalised maculopapular rash developed, which was non-itchy on the trunk, arms and legs with no fevers or other symptoms were associated ([figures 1 and 2](#F1 F2){ref-type="fig"}). On day 5, cervical lymphadenopathy was palpable and a large raised scaly patch resembling a herald patch was noted on the back of the torso ([figure 1](#F1){ref-type="fig"}). The rash persisted for 2 weeks with gradual resolution of the rash and the lymphadenopathy. Laboratory tests revealed a normal white blood cells and platelet count, normal liver and kidney function, normal C reactive protein and erythrocyte sedimentation rate. The patient remained otherwise healthy, and no medications were taken. An echocardiogram was also noted to be normal.

![Maculopapular exanthem on the trunk.](bcr-2020-237056f01){#F1}

![Maculopapular rash on the legs.](bcr-2020-237056f02){#F2}

There were no other symptoms apart from the cervical lymphadenopathy as patient had just recovered from COVID-19. The rash was non-itchy, and a differential diagnosis could have been pityriasis rosea due to a viral exanthema. Most causes of pityriasis rosea are unclear and are thought to be due to a viral trigger. Without any other symptoms apart from the cervical lymphadenopathy, due to the temporal effect of being infected with COVID-19, the rash and the cervical lymphadenopathy are most likely immune-mediated and triggered by SARS-CoV-2 virus.

Various cutaneous manifestations have been reported with COVID-19 during an acute clinical presentation from papulovesicular rash, urticaria, painful acral red purple papules, livedo reticularis lesions and petechiae.[@R1] While studies have reported that timing of cutaneous manifestations associated with COVID-19 have ranged in patients, from 3 days before COVID-19 diagnosis to 13 days after diagnosis.[@R2] There have been no reported cases of prolonged dermatological manifestations in children following recovery of COVID-19 4 weeks after diagnosis.

###### Learning points

-   Cutaneous manifestations have been reported with COVID-19 during an acute clinical presentation.

-   Unusual prolonged dermatological manifestation from a post-COVID-19 infection has rarely been reported.

-   Pityriasis rosea exanthem may be part of a cutaneous manifestations associated with COVID-19.
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